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Objective: Giant cell tumors are benign bone neoplasms that are relatively rare in adults
and  their biological behavior is still unpredictable. The incidence of local recurrence has
presented variation between 0% and 65% in studies conducted worldwide, but few data are
available on this complication in the Brazilian population.
Methods: Information on 155 patients with conﬁrmed histological diagnoses of giant cell
tumor who were treated in our institution’s orthopedic oncology service between January
2000  and July 2014 was gathered. Demographic characteristics were evaluated and compared
between patients who presented local recurrence during the clinical follow-up.
Results: Local recurrence was observed in 26 patients (16.7%), of whom 22 were female
(84.6%). The most common site of local recurrence was the distal femur (38.4%). Eleven
patients presented early recurrence, while 15 cases were diagnosed after 15 months, repre-
senting 42.3% and 57.7%, respectively. Metastases were identiﬁed in ﬁve patients (3.2%).
Conclusion: Tumor-related factors did not show any increased incidence of local recurrence
of  giant cell tumors. Surgical treatment with an intralesional margin is a valid option for
treating local recurrences and does not show any difference in disease-free survival in rela-
tion  to other types of procedures. Clinical treatment is reserved for cases of unresectable
tumors or when surgical treatment is impossible.©  2016 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier EditoraLtda. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
 Study conducted at Instituto Nacional de Traumatologia e Ortopedia (Into), Rio de Janeiro, RJ, Brazil.
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E-mail: oliveirajr.roberto@gmail.com (R.C. Júnior).
ttp://dx.doi.org/10.1016/j.rboe.2016.06.004
255-4971/© 2016 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora Ltda. This is an open access article
nder  the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Estudo  epidemiológico  de  recidiva  de  tumor  de  células  gigantes  no
Instituto  Nacional  de  Traumatologia  e  Ortopedia
Palavras-chave:
Tumores de células gigantes
Recidiva
Epidemiologia
r  e  s  u  m  o
Objetivos: O tumor de células gigantes (TCG) é uma neoplasia óssea benigna relativamente
rara em adultos, porém seu comportamento biológico ainda é imprevisível. A incidência de
recidiva local apresenta variac¸ão entre 0–65% em estudos internacionais, porém há poucos
dados referentes a essa complicac¸ão em nossa populac¸ão.
Métodos: Foram coletadas informac¸ões sobre 155 pacientes com diagnóstico histológico con-
ﬁrmado de TCG, acompanhados no servic¸o de oncologia ortopédica da nossa instituic¸ão, de
janeiro de 2000 a julho de 2014. As características demográﬁcas foram avaliadas e compara-
das  entre os pacientes que apresentaram recidiva local durante o seguimento clínico.
Resultados: Houve recidiva local em 26 pacientes (16,7%), dos quais 22 eram do sexo feminino
(84,6%). A localizac¸ão mais comum de recidiva local foi o fêmur distal (38,4%). Onze pacientes
apresentaram recidiva precoce, enquanto 15 casos foram diagnosticados após 15 meses, o
que  representa, respectivamente, 42,3% e 57,7%. Metástases foram identiﬁcadas em cinco
pacientes (3,2%).
Conclusão: Os fatores relacionados ao tumor não evidenciaram aumento da incidência de
recidiva local de tumor de células gigantes. O tratamento cirúrgico com margem intrale-
sional é uma opc¸ão válida no tratamento de recidivas locais e não apresenta diferenc¸a
de  sobrevida livre de doenc¸a entre outros tipos de procedimentos. Tratamento clínico é
reservado em casos de tumores irressecáveis ou impossibilidade de tratamento cirúrgico.
©  2016 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://Introduction
Giant cell tumor (GCT), or osteoclastoma, is a neoplasm of
indeterminate malignancy with locally aggressive behavior,
composed of mononuclear ovoid neoplastic tissue uniformly
interposed by numerous giant cells.1–3
GCT represents approximately 5% of primary bone tumors
and about 23% of benign bone tumors.2,4 It occurs most often
between 20 and 40 years of age, with a slight predominance in
females (ratio of 1.2:1). It is considered a rare tumor in children
and adolescents,5 and less than 10% of cases occur in patients
over 65 years.6
The most common location is the epiphyseal region of long
bones in skeletally mature individuals; it can also affect the
metaphyseal region of patients with open physis.1,2 The most
affected areas are the distal femur, proximal tibia and dis-
tal radius. Axial involvement is unusual.7 Despite its benign
behavior, this disease can develop with local complications
and metastasis, especially into the lungs.4,8,9
Relapse is deﬁned as symptomatic or radiologic evidence
of the disease, at least three months after the treatment,
and is generally detected within the ﬁrst two years of follow-
up.10 Recurrence rates of primary GCT range from 0% to 65%,
depending on the type of treatment and tumor site presenta-
tion. Despite their benign nature, pulmonary metastases occur
in 2–5% of cases.11
GCT is a relatively rare benign tumor in adults; however,
its biological behavior remains unpredictable. There are many
published studies that report the experiences of international
groups in developed countries, but there is little informa-
tion about the disease’s behavior in developing countries. Thiscreativecommons.org/licenses/by-nc-nd/4.0/).
article presents the epidemiological data of 155 patients, with
14 years of follow-up, in a Brazilian orthopedic reference
institution.
Methods
Data were collected on patients with conﬁrmed histological
diagnosis of GCT, followed-up at the Orthopedic Oncology
Service from January 2000 to July 2014. This study was
approved by the ethics committee of the institution.
Diagnostic investigation was conducted through clinical
and radiological evaluation, which included conventional
radiography, computed tomography, and magnetic resonance
imaging. Subsequently, the patients underwent needle biopsy
for histopathological deﬁnition.
The exclusion criteria were: local recurrence in less than
three months after surgery; loss to follow-up; and incomplete
clinical and radiological record.
The affected site, the presence of metastases and/or patho-
logical fractures, the period of symptoms evolution, clinical
and radiological staging and histopathological diagnosis were
assessed, as well as the type of surgery performed, surgi-
cal margin, and the use of adjuvants. The follow-up period,
disease-free time, and location/number of relapses were also
assessed.
Patients were divided into three groups, A, B, and C, accord-
ing to tumor site, as described by Takeuchi et al.12 Group
A included lesions in the femur, tibia, humerus, and radius.
Group B comprised tumors located in the scapula, ﬁbula, ulna
and hand or foot. Group included tumors located in the axial
skeleton.
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Tumor staging was followed the classiﬁcation by Cam-
anacci et al.,13 divided as follows: I – quiescent, intraosseous
esions; II – active, presenting intact periosteum; III – aggres-
ive, with cortex rupture and invasion of soft tissues. This
lassiﬁcation has therapeutic utility, and was used to help
eﬁne the surgical margin as intralesional, marginal, wide, or
adical.
Surgical treatment followed the protocol recommended by
he institution, which prioritizes less aggressive procedures
hat allow joint preservation. Among surgical treatments,
ntralesional resection associated with the use of spheri-
al dental bur was performed, followed by local ﬁlling of
one defects with polymethylmethacrylate (PMMA), autolo-
ous bone graft, or allograft. Extensive surgery was performed
n cases in which tumor extension prevented intralesional
esection or in tumors located in expendable bones, such as
he head of the ﬁbula or the distal ulna.
Clinical follow-up was done after 1, 3, 6, 12, 18, and
4 months. After 24 months, evaluations were performed
ccording to the recommendations of the attending physician.
valuations included physical examination and radiological
nvestigation (conventional and chest X-rays), in order to make
n early diagnosis of recurrences or metastases. In case of sus-
ected local recurrence, complementary imaging tests were
rdered, which included computed tomography and magnetic
esonance imaging.
The outcome of the patients included in this study were
lassiﬁed as favorable or unfavorable, according to the clinical
ollow-up. A favorable outcome indicated that the patient had
o local recurrence or metastasis during follow-up. Patients
ho  experienced these complications were placed in the unfa-
orable outcome group.
Table 1 – Demographic and tumor characteristics of 155 patient
Parameters Clinical outcome
Favorable
n  = 129
Age (years) 33.4 ± 13.4 
Gender
Male 43.4% (56/129) 
Female 56.6% (73/129) 
Campanacci classiﬁcation
I 4 
II 36 
III 86 
Tumor topography
Group A 94 
Group B 14 
Group C 6 
Evolution time
Mean ± SD (months) 12.9 ± 16.9 
Fracture at diagnosis
Yes 17 
No 112 
Topography: humerus, radius, femur, tibia.
Topography B: ulna, ﬁbula, talus.
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The data obtained was included in a database in Excel
2013 (Microsoft) and statistically assessed. The demographic
proﬁle was described as percentages, means, standard devia-
tions, and minimum and maximum values. A comparison of
the demographic characteristics of patients with and without
recurrence was made using the Mann–Whitney test and the
association was tested using the chi-squared test, at the 95%
signiﬁcance level. Event-free survival was assessed according
to follow-up time in months, considering the date of the ﬁrst
visit until the occurrence of the event (metastasis or recur-
rence). Patients who remained alive were contacted, and the
date of the last consultation was regarded as the end of follow-
up. The cumulative survival probabilities were estimated with
the Kaplan–Meier method and, for the statistical analysis of
the curves between clinical groups, the log-rank test was used.
All statistical tests were performed in GraphPad Prism version
5.00 for Windows (GraphPad Software – San Diego,  California,
USA. [www.graphpad.com]). A p-value < 0.05 was considered
to be statistically signiﬁcant.
Results
From January 2000 to July 2014, 158 patients were diagnosed in
our institution with GCT; of these, three were excluded from
the study, following the aforementioned exclusion criteria.
The analysis included 155 patients; 60 (38.7%) were male
and 95 (61.3%), female. The mean follow-up period was 56.7patients, representing 12.9% of cases.
Tumors were found mainly in long bones: 32.9% in the
femur (51/155), 29% in the tibia (45/155), and 16.7% in the
s with giant cell tumor.
Total p-value
Unfavorable
n  = 26
34.0 ± 14.8 33.0 ± 13.5 0.9218
15.4% (4/26) 60 0.0078
84.6% (22/26) 95
– 4 0.4726
9 45
15 201
22 116 0.0994
3 16
1 8
12.7 ± 16.8 12.9 ± 16.9 0.6592
2 19 0.7425
24 126
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Table 2 – Surgical treatment of 149 patients with giant cell tumor.
Parameter Primary tumor Relapse Total
Type of surgery
1 Curettage + polymethylmethacrylate 39 15 54
2 Curettage + graft 6 1 7
3 Wide margin resection + endoprosthesis 27 3 30
4 Wide margin resection + bone lengthening 3 0 3
5 Wide margin resection + ﬁbula transplant 8 0 8
6 Resection 12 1 13
7 Amputation 21 2 23
8 Others 8 3 11
Surgical margin
1  Intralesional 42 17 59
2 Marginal 10 1 11
3 Wide 61 5 66
Gouin et al.14 did not observe any tumor-related risk fac-
tors that increase the incidence of local recurrence after
intralesional treatment in appendicular skeleton injuries.
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radius (26/155), as shown in Table 1. Group A totaled 123 cases
(79.3%), while B group had 25 (16.2%). A minority of patients
were included in group C (seven cases, 4.5%).
According to the Campanacci radiological classiﬁcation,
grades I, II, and III represented, respectively, 2.7% (4/150), 30%
(45/150), and 67.3% (101/150) of the patients. Five patients had
no radiographic records in the image  bank, therefore were
excluded due to this criterion.
One hundred and ﬁfty patients underwent surgical treat-
ment of the primary lesion, three of them in another
institution. One of the cases was not included in the present
analysis, as no information on the procedure performed could
be obtained (Table 2). Five patients were not treated surgically,
as they did not agree with the proposed procedure. Resection
with intralesional margin was accomplished in 39.3% (59/150)
of patients; 44% (66/150) underwent treatment with wide mar-
gin. Marginal and radical margins accounted for 7.3% (11/150)
and 8.6% (13/150) of the cases, respectively. The most com-
monly performed procedure was curettage associated with
the use of PMMA  (36%, 54/150), followed by wide resection
with use of unconventional endoprosthesis (20%; 30/150) and
amputation (15.3%; 23/150).
Local recurrence was observed in 26 patients (16.7%). The
demographic characteristics and treatment data of patients
with and without recurrence were compared. Soft tissue lesion
was identiﬁed in six cases. Fifteen patients aged between 20
and 40 years at the diagnosis of the primary tumor were iden-
tiﬁed, accounting for 57.7% of relapsed cases. Eight patients
(30.7%) were aged over 40 years at initial diagnosis. Regarding
the gender, 22 patients were female (84.6%).
One patient from the group that presented recurrence had
pulmonary metastasis. In ﬁve years, event-free survival was
88% (Fig. 1). Considering the Campanacci groups, there was
no difference in event-free survival at ﬁve years: 88.5% for
Campanacci II and 91.5% for Campanacci III (Fig. 2A). Simi-
larly, considering the topography of groups, there was also no
difference in event-free survival (Fig. 2B).
The highest number of recurrences was observed in Group
A (n = 22; 84.6%), followed by Group B (n = 3; 11.5%), and group
C (n = 1; 3.8%). The most common site of local recurrence
was the distal femur (n = 10; 38.4%). Eleven patients had early
recurrence while 15 cases were diagnosed after 15 months,11 2 13
representing 42.3% and 57.7%, respectively. Fifteen patients
who had undergone curettage and use of PMMA  developed
local recurrence.
Twenty-four patients diagnosed with local recurrence were
treated surgically, six of whom (25%) underwent new curet-
tage associated with the use of PMMA. Five cases (20.8%) were
treated by wide resection and use of endoprosthesis, while
four patients (16.6%) underwent amputation. Two patients did
not undergo surgery because they did not accept the surgi-
cal indication, and were submitted to clinical treatment with
the use of bisphosphonates (alendronate). Four patients pre-
sented new recurrence after the second surgery, and one case
had a third relapse.
Metastases were observed in ﬁve patients (3.2%), among
whom only one had local recurrence during evolution. All
metastases were diagnosed in the lungs.
After clinical follow-up, 30 patients diagnosed with primary
GCT (19.3%) had an unfavorable outcome; 25 with diagnosis of
local recurrence, four with metastases, and one who devel-
oped both complications.
Discussion40
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Fig. 1 – Event-free survival at ﬁve years.
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Fig. 2 – Event-free survival in patients with giant cell tumor regarding the Campanacci classiﬁcation (A) and topography (B).
Group A included lesions in the femur, tibia, humerus, and radius. Group B comprised tumors located in the scapula, ﬁbula,
ulna, and bones of the hands or feet. Group C comprised tumors located in the axial skeleton.
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this indicates that the factors related to reduced risk of
ocal recurrence were effectiveness and earliness of surgical
reatment.12,14 The risk of local recurrence in tumors located
n the distal radius and proximal femur was higher, although
t was not statistically signiﬁcant. The use of autograft was
onsidered an independent risk factor for local recurrence.14
xtension to soft tissues and radiological aggressiveness
ere also reported as prognostic factors, what highlights
he importance of the Campanacci classiﬁcation.13–15 In a
eta-analysis, Li et al.16 indicated that age younger than 20
ears, tumors located in the distal radius, and intralesional
urgery with or without bone grafting may be risk factors
or relapse in appendicular tumors, but this was not statisti-
ally conﬁrmed.16 In the present study, the sites with highest
ocal recurrence rate were the distal femur, proximal tibia, and
istal radius. The demographic parameters evaluated herein,
uch as gender, age, location, and radiological classiﬁcation,
ere not signiﬁcantly related to the clinical outcome.
Several factors are important when interpreting the results.
n this study, three patients who had been previously treated
n other institutions were included. This may limit the con-
lusions about the recurrence rate of these patients, since it
as not possible to obtain consistent intraoperative data. In
ddition, our institution is a reference that receives patients
rom other locations, which may affect the follow-up.
Surgical treatment with local disease control, combined
ith local adjuvant, is the standard care for appendicular
esions in our institution. The risk of recurrence in these
ases is 12–18%, consistent with the data obtained.14,15 The
reatment used for primary lesions was intralesional curet-
age followed by enlargement of the cavity with a spherical
ental bur. This surgical option is less invasive and usually
llows the joint and adjacent tissue to remain disease-free.
he adjuvant options are PMMA,  hydrogen peroxide, phenol,
nd cryotherapy. PMMA  is the compound most widely used in
ur institution due to its availability, ease of application, and
roven efﬁcacy. The impact of PMMA  is related to the toxic and
hermal effects that occur after application, which promote
15etter local control. Wide margin surgery was indicated in
ases where tumor extent prevented intralesional resection
r tumors involving expendable bones, such as the head of
he ﬁbula and distal ulna.11Pelvic injuries are rare, representing approximately
1.5–6.1% of cases, but they are more  associated with early
recurrence and metastasis (7–75% and 2–9.1% of patients,
respectively). Due to their location, some cases may be con-
sidered unresectable. There is no standard treatment for GCT
in the pelvis. Although curettage preserves the integrity of the
pelvis, local recurrence rate ranges from 6.3% to 43%. Wide
resection is intended to prevent recurrence, but is associ-
ated with high rates of complications.17 Three cases of pelvic
lesions (1.9%) were found, two in the ischium and one in
the acetabulum. Local recurrence occurred in one case, after
tumor resection from the ischium. According to Guo et al.,17
the wide resection of pelvic lesions presents a lower rate of
recurrences, with good functional results. These data are con-
sistent with the clinical outcomes observed in the present
study.
GCT located in the axial skeleton represent 3–7% of cases of
bone GCT and up to 4% of vertebral bone tumors. Treatment
of these lesions is a challenge, as surgery with intralesional
margin is considered to be a technically complex procedure
with low effectiveness. Wide resection with free margins is
hardly feasible, due to the associated risk. Embolization can
reduce intraoperative bleeding. Radiotherapy has been suc-
cessfully employed in some sacral lesions, particularly when it
is a relapse.18 In the present study, two sacral tumors and two
lumbar tumors were observed, with overall incidence of 2.5%
of cases. Two patients underwent surgical treatment: corpec-
tomy, and anterior and posterior arthrodesis. One patient later
received radiation therapy and arterial embolization. Only one
patient did not undergo surgery, due to refusal of the proposed
treatment. There was no evidence of recurrence during the
clinical follow-up (mean of 3.8 years).
Yanagisawa et al.19 described 11 cases of GCT distal to the
radiocarpal and tibiotarsal joints; ﬁve patients were male and
six female, with a mean of 24.7 years. The location and the
most frequent radiological classiﬁcation were, respectively,
the metacarpals (45.45%) and Campanacci II (54.54%). In the
present study, 13 patients were diagnosed with lesions in the
aforementioned topography. The most common sites were
the metacarpals (4/13) and tarsal bones (4/13). The patients
with injuries classiﬁed as Campanacci I or IIwere surgi-
cally treated with intralesional margin excision. The cases
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classiﬁed as Campanacci IIIwere  treated with radical margin
– either amputation or en bloc resection (27.2%). There were
two cases of local recurrence and one case of lung metastasis.
This ﬁnding was consistent with previous studies.19
The treatment of tumor recurrence is considered con-
troversial. According to Klenke et al.,11 resection with wide
margins is the most appropriate option, due to lower recur-
rence rates and longer disease-free survival. Nevertheless,
surgery with intralesional margin is a valid option in the
treatment of recurrent GCT. This treatment should be used
regardless of tumor extension to soft tissues; wide mar-
gin resection should be reserved for cases where there is
extensive bone involvement or injury to the neurovascular
structures. Wide margin resection often requires complex
bone reconstructions, associated with higher rates of surgi-
cal complications and functional deﬁcit. The potential risk of
lung metastases is not associated with the type of surgery
performed.11,12
Recent studies indicate the use of speciﬁc clinical
treatment in cases of tumors that are considered to be
unresectable, especially those in the sacrum and spine. The
recommended drugs include bisphosphonates and deno-
sumab, which inhibit the receptor activator of nuclear factor
kappa B (RANK) system.20,21 In the present study, two patients
diagnosed with local recurrence did not undergo surgery, as
they did not accept the proposed procedure. The use of bis-
phosphonates (alendronate) was offered as a treatment option
in these cases, achieving good local control during follow-up.
The metastasis rate found in the present study is consistent
with that of the literature. Five patients (3.2%) had lung metas-
tases, among whom only one had local recurrence during the
follow-up.4,22
Metastases occur primarily in the lungs, and their inci-
dence is between 1% and 9%.22 Risk factors for this event
include primary site, local recurrence, and type of primary
tumor treatment. The interval between the diagnosis of
the primary tumor and the detection of metastases ranges
between 0 and 10 years (mean of 3.5). The most common
primary metastasis sites is the distal radius, followed by
the femur and sacrum. Local aggressiveness and multiple
recurrences have been associated with increased incidence of
metastases.22 Five patients (3.2%) had lung metastases, among
whom there was one case of local recurrence during follow-
up. The primary sites were the distal tibia (2/5), distal radius
(1/5), metacarpal (1/5), and proximal humerus (1/5). There was
no statistical association between local recurrence or tumor
location on the incidence of metastasis.
Conclusion
GCT recurrence was observed in 26 patients (16.7%). The
factors related to the tumor did not evidence an increased
incidence of this complication, although it was more  com-
mon  in females. Surgical treatment with intralesional margin
is a valid option for the treatment of local recurrences and
presents no difference regarding disease-free survival when
compared to other procedures. Clinical treatment is used in
cases of unresectable tumors or surgical treatment impossi-
bility.
21 6;5 1(4):459–465
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